Qiagen NVQGEN
▲ PositiveCapitalrelevance
Q2 sales and EPS exceeded outlook, reaffirming full-year guidance.
Impact on stocks 1
Biotech & Genomic Medicine
Qiagen NVQIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth
Earnings
QIAGEN reported second-quarter 2026 net sales of $535 million, unchanged from the prior year and exceeding its outlook for an approximately 2% decline at constant exchange rates. The company's growth pillars together delivered about 5% CER growth, led by Sample technologies, QIAcuity, and QIAGEN Digital Insights, while QuantiFERON sales rose slightly amid lower U.S. immigration testing demand. Adjusted diluted earnings per share came in at $0.62, above the forecast of at least $0.60 CER, and the adjusted operating income margin held at 29.4%. QIAGEN reaffirmed its full-year 2026 guidance for net sales growth of about 1-2% CER and adjusted diluted EPS of at least $2.43 CER.
Qiagen NVQ2 sales and EPS exceeded outlook, reaffirming full-year guidance.